Fig. 3
From: Auto-antibodies against carbonyl-modified vimentin in COPD: potential role as a biomarker
Sensitivity of immunoreactivity for IgM (panel A) and IgG (panel B) against carbonyl-modified Vimentin in control (non-smokers (NS) and smokers) and subjects with COPD as defined by lung function. Sensitivity was determined as the percentage of subjects in each group exhibiting antibody titres above the threshold, as defined in Fig. 1, for IgM and IgG, respectively